Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIFU with Toripalimab and Regorafenib in Metastatic Colorectal Cancer
NCT04819516Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2020
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of toripalimab and regorafenib in colorectal cancer (CRC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Adverse events at 12 months. Started Dec 2020; status: recruiting.
02
Drugs
toripalimabregorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04819516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04819516.